Treatment | Clearance (Mean ± S.D.) |
---|---|
(μl / mg / min) | |
0.3 μM TUDC | N.D. |
+1 μM LTC4 | N.D. |
+3 mM MeSG | N.D. |
+100 μM MTX | N.D. |
+10 μM TLCS | N.D. |
+100 μM TUDC | 4.7 ± 1.6* |
+20 μM E217G | 8.7 ± 2.3* |
+50 μM E23G | 14.4 ± 1.9* |
LTC4, leukotriene C4; MTX, methotrexate; MeSG, S-methyl-glutathione; TLCS, taurolithocholate sulfate.
↵* Transport in MRP2-expressing membrane vesicles significantly different (P < 0.05) from that in control (EV) membrane vesicles.